

ERAVAC[®]

Inactivated, adjuvanted vaccine (RHDV2)

FLIP-OFF SYSTEM



INACTIVATED VACCINE:

Active immunization for the reduction of mortality caused by RHDV2



EASY MANAGEMENT:

Ready to use product



WHITISH:

Emulsion, also available in 10 and 40 multidoses



MONOVALENT VACCINE:

Flexibility in protocols and ability to manage each case individually

LOVE AT FIRST SIGHT, PROTECTION FROM ITS FIRST HOPS




Vaccination from **30 DAYS** of age



Onset of immunity: **1 WEEK**



Duration of immunity: **12 MONTHS**



Safety studies conducted in **PET RABBITS**



Also available for **GESTATING FEMALES**



Whitish and **READY TO USE** product

ERAVAC[®]

Inactivated, adjuvanted vaccine (RHDV2)

FROM ITS FIRST HOPS



The only RHDV2 vaccine that can be administered from 30 days of age

REFERENCES:

- 1) OIE. 2018. OIE Terrestrial Manual 2018. Rabbit haemorrhagic disease. https://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/3.06.02_RHD.pdf
- 2) Dalton, K.P.; Nicieza, I.; Balseiro, A.; Muguerza, M.A.; Rosell, J.M.; Casois, R.; Alvarez, A.L.; Parra, F. Variant rabbit hemorrhagic disease virus in young rabbits, Spain. *Emerg. Infect. Dis.* 18, 2009–2012 (2012).
- 3) Rachel E. Marschang; Karola Weider; Hanna Erhard; Eva-Maria Klas; Claudia Laik-Schandelmaier. RABBIT HEMORRHAGIC DISEASE VIRUSES DETECTED IN PET RABBITS IN A COMMERCIAL LABORATORY IN EUROPE, *The End-to-end Journal* (2018).
- 4) Baratelli M.; Molist-Badiola J.; Puigredon-Fontanet A.; Pascual M.; Boix O.; Mora-Igual F.X.; Woodward M.; Lavazza A.; Capucci L. Characterization of the maternally derived antibody immunity against RHDV-2 after administration in breeding does of an inactivated vaccine. *Vaccines* 2020, 8, 484.
- 5) EMA - Eravac EPAR - Product information. https://www.ema.europa.eu/en/documents/assessment-report/eravac-epar-public-assessment-report_en.pdf

ERAVAC[®]: Inactivated vaccine, rabbit haemorrhagic disease type 2 virus (RHDV2), in injectable emulsion. **COMPOSITION:** Each dose of 0.5 ml contains: Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037 70% cELISA40*, (*) 70 % of vaccinated rabbits shall give cELISA antibody titres equal to or higher than 40. **INDICATIONS:** Rabbits: For active immunisation of rabbits from the age of 30 days to reduce mortality caused by the rabbit haemorrhagic disease type 2 virus (RHDV2). **ADMINISTRATION ROUTE:** Subcutaneous use. **DOSAGE:** 0.5 ml/animal. **ADVERSE REACTIONS:** A transient temperature increase slightly above 40 °C might very commonly occur between two or three days following vaccination. This slight temperature increase resolves spontaneously without treatment by day 5 post-vaccination. Nodules or swelling (< 2 cm) can be very commonly observed in the injection site, which may last 24 hours. These local reactions gradually reduce and disappear without need for treatment. Lethargy and/or inappetence may be observed very rarely in the first 48 hours after injection based on postauthorisation pharmacovigilance reporting. **WITHDRAWAL TIME:** 0 days. **SPECIAL PRECAUTIONS:** The vaccine provides protection only against RHDV2, cross protection against classical RHDV has not been demonstrated. Vaccination is recommended where RHDV2 is epidemiologically relevant. Vaccinate only healthy rabbits. Do not mix with any other veterinary medicinal products. Special precautions to be taken by the person administering the product: This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. Store and transport refrigerated (2°C – 8 °C). Do not freeze. Keep the bottle in the outer carton in order to protect from light. Use product immediately after opening. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. Keep out of the reach and sight of children. **FURTHER INFORMATION:** Onset of immunity: 1 week. Duration of immunity: 12 months demonstrated by challenge. Pregnancy: Laboratory studies in doe rabbits in the last third of gestation have not produced any evidence of a teratogenic, foetotoxic and maternotoxic effects. Pregnant does should be handled with special care to avoid stress and risk of abortion. **PACKAGING:** 10 vials of 1 dose, 1 vial of 10 doses, 1 vial of 40 doses. **MARKETING AUTHORISATION NUMBER(S):** EU/2/16/199/001-002-003. **MARKETING AUTHORISATION HOLDER:** Laboratorios Hipra S.A. Avda. La Selva, 135, 17170 Amer (Girona), SPAIN. Under veterinary prescription. Use medicines responsibly.

HIPRA

HIPRA UK and IRELAND
Hipra UK and Ireland, Ltd., Foxhall Business Centre, Foxhall Lodge, Foxhall Road, Nottingham, NG7 6LH. Reino Unido
Tel.: (+44) 0115 845 6486 - ukandireland@hipra.com - www.hipra.com



The Reference
in Prevention
for Animal Health

WHY EARLY VACCINATION?

Rabbit haemorrhagic disease virus 2 (RHDV2) is a highly infectious and pathogenic Calicivirus that causes lethal hepatitis and haemorrhages in internal organs, frequently with sudden death, being difficult to diagnose¹.

- Unlike RHDV1, it affects **YOUNG RABBITS** (<30 days of age).
- Young rabbits present **HIGHER MORTALITY** than adults².
- RHDV2 has largely replaced RHDV1.

VACCINATING RABBITS IS THE PRIMARY METHOD FOR THE PREVENTION OF RHDV2

ERAVAC® IS...

LOVE FROM THE **FIRST DAY**

1) Kits from vaccinated mothers are BORN WITH MATERNALLY DERIVED ANTIBODIES (MDAs) against RHDV2, transmitted through the placenta⁴:

- Protection from the first day of life.
- Protection while they are most susceptible.



Antibody (Ab) creation after vaccination of the doe




Transplacental transmission of Ab to the kits



Kits born with MDAs

2) EFFECTIVE EVEN IN THE PRESENCE OF MDAs in 1-month old animals (100% survival after challenge)⁵.



MDAs are no longer detectable from approximately 30 days of age⁴




Ab creation after vaccination, with no interference with the remaining MDAs

EARLY IN LIFE PROTECTION

 Safety and seroconversion study⁵:

- ERAVAC® can be administered to pet rabbits from 30 days of age
- All vaccinated animals responded serologically to ERAVAC® inducing high antibody responses compared to the negative response in the control group.

FAST ACTING AGAINST RHDV2

 Onset of immunity: **1 WEEK AFTER VACCINATION**. (Two different studies show 100% and 93% of survival after challenge at 7 days post-vaccination)⁵.

- Prompt protection to non-vaccinated and young rabbits after losing their MDAs.
- Fast onset of immunity in the event of an outbreak¹.
- Early immunization of pregnant does, so that they have time to transmit MDAs to their offspring before delivering.

LONG-LASTING IMMUNITY

 Duration of immunity: **12 MONTHS**, demonstrated by challenge.